CO2020013545A2 - Formulación estable de anticuerpos - Google Patents

Formulación estable de anticuerpos

Info

Publication number
CO2020013545A2
CO2020013545A2 CONC2020/0013545A CO2020013545A CO2020013545A2 CO 2020013545 A2 CO2020013545 A2 CO 2020013545A2 CO 2020013545 A CO2020013545 A CO 2020013545A CO 2020013545 A2 CO2020013545 A2 CO 2020013545A2
Authority
CO
Colombia
Prior art keywords
antibody formulation
stable antibody
formulation
antibody
formulations
Prior art date
Application number
CONC2020/0013545A
Other languages
English (en)
Spanish (es)
Inventor
Murali Jayaraman
Anuja Chandrasekar
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68164052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2020013545(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of CO2020013545A2 publication Critical patent/CO2020013545A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CONC2020/0013545A 2018-04-10 2020-10-28 Formulación estable de anticuerpos CO2020013545A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841013645 2018-04-10
PCT/IN2019/050291 WO2019198099A1 (en) 2018-04-10 2019-04-10 Stable antibody formulation

Publications (1)

Publication Number Publication Date
CO2020013545A2 true CO2020013545A2 (es) 2021-01-18

Family

ID=68164052

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0013545A CO2020013545A2 (es) 2018-04-10 2020-10-28 Formulación estable de anticuerpos

Country Status (10)

Country Link
US (1) US12024561B2 (https=)
EP (1) EP3773695A4 (https=)
JP (1) JP2021521168A (https=)
CN (1) CN112243379A (https=)
AU (1) AU2019251452A1 (https=)
BR (1) BR112020020741A2 (https=)
CO (1) CO2020013545A2 (https=)
SG (1) SG11202009872YA (https=)
WO (1) WO2019198099A1 (https=)
ZA (1) ZA202006262B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358763C2 (ru) * 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) * 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
AU2019251453A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy’S Laboratories Limited Stable formulations of therapeutic antibody
US12030948B2 (en) * 2018-04-10 2024-07-09 Dr. Reddy's Laboratories Limited Antibody formulation
US20220267449A1 (en) * 2019-06-10 2022-08-25 Takeda Pharmaceutical Company Limited METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY
AU2020290999A1 (en) * 2019-06-10 2022-02-03 Takeda Pharmaceutical Company Limited Antibody purification methods and compositions thereof

Also Published As

Publication number Publication date
SG11202009872YA (en) 2020-11-27
EP3773695A4 (en) 2021-12-22
EP3773695A1 (en) 2021-02-17
AU2019251452A1 (en) 2020-11-26
JP2021521168A (ja) 2021-08-26
ZA202006262B (en) 2023-01-25
BR112020020741A2 (pt) 2021-01-19
US12024561B2 (en) 2024-07-02
AU2019251452A2 (en) 2020-12-03
WO2019198099A1 (en) 2019-10-17
CN112243379A (zh) 2021-01-19
US20210253714A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CO2020013571A2 (es) Formulaciones estables de anticuerpos terapéuticos
CO2019011021A2 (es) Formulacion estable de anticuerpos
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
MX2025010757A (es) Formulacion farmaceutica de ph bajo
MX2021014863A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
MX385109B (es) Formulaciones de anticuerpos.
CO2020016008A2 (es) Formulación de proteína de fusión estable
BR112016026811A2 (pt) formulação de anticorpo
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
CO2022005737A2 (es) Formulación estable de anticuerpo de integrina
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos
AR095396A1 (es) Formulaciones de anticuerpo
WO2018075692A3 (en) Antibody constructs
AR108631A1 (es) Formulación de neurotoxinas
CO2020016014A2 (es) Formulación de proteína de fusión ctla4-ig
MX380569B (es) Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico.
CO2020013545A2 (es) Formulación estable de anticuerpos
MX2021005910A (es) Formulacion de proteina de alta concentracion.
AR117407A1 (es) Formulaciones acuosas estables de anticuerpos anti-tau
MX2020004675A (es) Formulaciones de alcohol de seda.
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
BR112023002984A2 (pt) Formulações de anticorpo terapêutico
BR112018011590A2 (pt) formulação cosmética
AR106510A1 (es) Formulaciones de anticuerpo antifactor d